蒙牛乳業(02319.HK)發行2030年及2035年可持續發展債券 總額35億元人民幣
格隆匯7月24日丨蒙牛乳業(02319.HK)發佈公告,2025年7月23日,公司就發行2030年到期的人民幣20億元2.0釐的可持續發展債券及2035年到期的人民幣15億元2.3釐的可持續發展債券(統稱“債券”),與聯席牽頭經辦人及聯席賬簿管理人訂立認購協議。
公司擬將債券發行的所得款項淨額(經扣除包銷傭金及有關發售的其他估計應付開支後)用於根據國家發改委證明爲其若幹現有債務進行再融資。發售債券所得款項淨額相等金額將分配至公司可持續融資框架中列明的若幹綠色合資格類別及社會責任合資格類別。公司將向聯交所申請各系列的債券以僅向專業投資者發行債券的方式上市及買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.